The latest price target for Pacific Biosciences (NASDAQ:PACB) was reported by Piper Sandler on February 20, 2025. The analyst firm set a price target for $2.00 expecting PACB to rise to within 12 months (a possible 30.72% upside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for Pacific Biosciences (NASDAQ:PACB) was provided by Piper Sandler, and Pacific Biosciences reiterated their neutral rating.

The last upgrade for Pacific Biosciences of California Inc happened on November 17, 2023 when UBS raised their price target to $10. UBS previously had a neutral for Pacific Biosciences of California Inc.

The last downgrade for Pacific Biosciences of California Inc happened on November 11, 2024 when UBS changed their price target from N/A to $2 for Pacific Biosciences of California Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacific Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacific Biosciences was filed on February 20, 2025 so you should expect the next rating to be made available sometime around February 20, 2026.

While ratings are subjective and will change, the latest Pacific Biosciences (PACB) rating was a reiterated with a price target of $2.50 to $2.00. The current price Pacific Biosciences (PACB) is trading at is $1.53, which is out of the analyst’s predicted range.